13
Jul
2009
Posted in I - Series C, Q - 2Q09, R - WEST, X - GI, X - Hepatology, XX - CA
Hyperion Therapeutics (San Francisco, CA) a clinical-stage specialty pharmaceutical company focused on gastroenterology and hepatology, closed a $60M Series C financing. Participants include Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates, Sofinnova Ventures, and WRF Capital.